United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Healthcare Industry News Frontage Laboratories adds oncology and radiolabeled capacity to Secaucus Phase I unit for integrated CRDMO execution Frontage Laboratories expands early-phase clinical research in U.S. and China. Find out how its oncology and AME focus could reshape sponsor strategies. bySrinathFebruary 2, 2026